SurgiMab Advances SGM-101, a Novel Fluorescent Tumor-specific Antibody, Into Pivotal Phase 3 Clinical Trial to Improve Surgical Outcomes in Colorectal Cancer Patients
SGM-101 has the potential to be the first tumor-targeted fluorescent probe to be marketed for fluorescence-guided surgery (FGS)
MONTPELLIER, France, July 16, 2019 -- (Healthcare Sales & Marketing Network) -- SurgiMab, a late-stage biotechnology company... Diagnostics, Oncology, Surgery SurgiMab, fluorescence-guided surgery
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Biotechnology | Cancer | Cancer & Oncology | Clinical Trials | Colorectal Cancer | France Health | Marketing | Pharmaceuticals